Viemed Healthcare Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Viemed Healthcare kazanç ve gelirinin sırasıyla yıllık 32.5% ve 12.9% oranında artması tahmin edilirken, EPS'nin yıllık 23.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

32.5%

Kazanç büyüme oranı

23.6%

EPS büyüme oranı

Healthcare kazanç büyümesi	20.8%
Gelir büyüme oranı	12.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	08 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Apr 11

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Mar 07

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	287	21	N/A	54	1
12/31/2025	253	16	N/A	45	3
12/31/2024	224	11	N/A	39	3
9/30/2024	214	10	4	37	N/A
6/30/2024	206	9	8	38	N/A
3/31/2024	194	10	8	36	N/A
12/31/2023	183	10	19	45	N/A
9/30/2023	170	9	16	40	N/A
6/30/2023	156	7	11	34	N/A
3/31/2023	146	6	7	31	N/A
12/31/2022	139	6	5	28	N/A
9/30/2022	133	8	5	29	N/A
6/30/2022	127	9	0	26	N/A
3/31/2022	121	9	3	25	N/A
12/31/2021	117	9	3	22	N/A
9/30/2021	116	10	2	20	N/A
6/30/2021	120	11	10	22	N/A
3/31/2021	136	29	29	39	N/A
12/31/2020	131	32	22	35	N/A
9/30/2020	122	29	26	37	N/A
6/30/2020	108	29	24	35	N/A
3/31/2020	86	11	2	19	N/A
12/31/2019	80	9	6	19	N/A
9/30/2019	76	9	7	20	N/A
6/30/2019	73	8	8	19	N/A
3/31/2019	68	9	16	22	N/A
12/31/2018	64	10	16	22	N/A
9/30/2018	60	7	11	15	N/A
6/30/2018	56	9	N/A	13	N/A
3/31/2018	51	8	N/A	9	N/A
12/31/2017	47	8	N/A	12	N/A
9/30/2017	43	11	N/A	14	N/A
12/31/2016	31	1	N/A	6	N/A
12/31/2015	38	10	N/A	10	N/A
12/31/2014	23	9	N/A	8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VMD 'nin tahmini kazanç büyümesi (yıllık 32.5% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: VMD şirketinin kazançlarının (yıllık 32.5% ) US pazarından (yıllık 15.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: VMD şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: VMD şirketinin gelirinin (yıllık 12.9% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VMD şirketinin gelirinin (yıllık 12.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VMD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Viemed Healthcare Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Consensus EPS estimates fall by 12%

Price target decreased by 7.8% to US$12.75

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Consensus EPS estimates fall by 19%

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 7.8% to US$12.75

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Consensus EPS estimates fall by 19%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

CEO & Director exercised options and sold US$182k worth of stock

Third quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Price target increased by 15% to US$15.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

Insufficient new directors

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Viemed Healthcare: Comments On Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Healthcare Q2 2022 Earnings Preview

Viemed Announces Management Appointments

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare: New Bullish Trend Has Just Begun

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Viemed Healthcare, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Viemed Healthcare EPS misses by $0.01, revenue in-line

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$10.80

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

Investor sentiment improved over the past week

New 90-day high: US$9.83

Strong Execution By Insider-Owners Ensures Viemed's Growth

Viemed Healthcare Announces Recent Publication of Non-Invasive Ventilation Study

New 90-day low: US$7.92

Viemed Healthcare, Inc. (TSX:VMD) acquired 5% stake in VeruStat, Inc for approximately $0.6 million.

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Third quarter 2020 earnings released: EPS US$0.072

Revenue beats expectations, earnings disappoint

Viemed Healthcare EPS misses by $0.02, beats on revenue

Market pulls back on stock over the past week

New 90-day low: US$8.01

New 90-day low - US$8.92

First half earnings released